Stemline Therapeutics Inc (NASDAQ:STML) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

Other research analysts have also recently issued reports about the company. Cowen and Company reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, May 12th. HC Wainwright reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, May 15th. Wedbush dropped their price objective on Stemline Therapeutics from $19.00 to $11.00 and set an “outperform” rating for the company in a research note on Monday, February 6th. Jefferies Group LLC set a $16.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 3rd. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, February 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $29.17.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ:STML) opened at 8.35 on Friday. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $14.60. The firm’s market capitalization is $195.19 million. The stock’s 50 day moving average is $8.44 and its 200-day moving average is $9.86.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative net margin of 4,058.44% and a negative return on equity of 50.06%. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts expect that Stemline Therapeutics will post ($2.26) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/20/stemline-therapeutics-inc-stml-upgraded-by-zacks-investment-research-to-hold.html.

In other news, CEO Ivan Bergstein sold 17,980 shares of Stemline Therapeutics stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $125,680.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 4,000 shares of Stemline Therapeutics stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,493 shares of company stock worth $331,676. Company insiders own 16.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors raised its position in Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 858 shares during the period. Perceptive Advisors LLC purchased a new stake in Stemline Therapeutics during the fourth quarter valued at about $115,000. Wells Fargo & Company MN increased its stake in Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Stemline Therapeutics during the first quarter valued at about $120,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares during the period. 37.76% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

12 Month Chart for NASDAQ:STML

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.